Clinical trials
HER2 + Breast Cancer clinical trials
Below are recruiting her2 + breast cancer clinical trials, each written for real people, not researchers. We’re tracking 952 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05945732Recruiting
Testing T-DXd or chemo for HER2-low or HR-positive breast cancer
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
GrazAges 18 years+ - NCT05950945RecruitingPhase 3
Trastuzumab deruxtecan for HER2-low metastatic breast cancer
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
Miami Beach, FloridaAges 18 years+ - NCT05930483Recruiting
Remote weight loss program for Hispanic/Latina breast cancer survivors
This trial tests a community-style, online (remote) weight loss program for people who finished breast cancer treatment and are now trying to improve health and weight. It may help by supporting safer weight loss through diet/energy reduction and physical activity.
Seattle, WashingtonAges 18 years+ - NCT05919108RecruitingPhase 2
Neratinib before surgery for HER2-mutated invasive lobular breast cancer
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05878314Recruiting
Testing how hormones and tumor markers guide breast cancer treatment
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
TübingenAges 18 years+ - NCT05893966Recruiting
Tested extra radiation to the tumor area in HER2-positive breast cancer
This study follows people with HER2-positive invasive breast cancer to see how adding radiation to the tumor bed may affect outcomes. It may be most relevant if you are scheduled for breast radiation and have not had radiation to the same side before.
Seoul, SeoulAges 19 years+ - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Gilbert, ArizonaAges 18 years+ - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
New Haven, ConnecticutAges 18 years+ - NCT05858398Recruiting
How body composition affects chemotherapy results in breast cancer
This study looks at whether body fat and muscle (body composition) change how well certain chemotherapy works after surgery for early breast cancer. You may be considered if you are planned to receive docetaxel as adjuvant (after-surgery) chemotherapy and have recent CT scan images.
RouenAges 18 years+ - NCT05877859Recruiting
Testing pembrolizumab with chemo before breast cancer surgery
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy before surgery improves immune and clinical responses in people with early-stage triple-negative breast cancer. You may benefit by getting a potentially more effective treatment plan, while the study team closely monitors your response.
Atlanta, GeorgiaAges 18 years+ - NCT05868226RecruitingPhase 1/Phase 2
Personalized cancer treatment study for advanced solid tumors
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
Birmingham, AlabamaAges 18 years+ - NCT05837455RecruitingPhase 2
Biomarker-guided treatment for early breast cancer before surgery
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
St Louis, MissouriAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT05846789RecruitingPhase 2
Tocilizumab plus chemo for metastatic breast cancer
This trial tests whether adding tocilizumab, a drug that calms the immune system, to standard chemotherapy helps control certain advanced breast cancers. It is for people with triple-negative or ER-positive, HER2-negative breast cancer that has spread or come back.
Atlanta, GeorgiaAges 18 years+ - NCT05831878Recruiting
Drug RC48 for HER2-low or HER2-ultralow breast cancer
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
ShanghaiAges 18 years+ - NCT05786664Recruiting
Breast cancer survivor study collecting your health samples
This study invites women who finished treatment for non-metastatic invasive breast cancer to share health information and biological samples for future research. It may help scientists understand survivorship and improve care after treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT05769010RecruitingPhase 2
HER2-positive or low breast cancer brain metastasis drug study
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Zhengzhou, HenanAges 18–75 - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT05736367Recruiting
Study tumor metabolism in certain types of breast cancer surgery
This study looks at how breast cancer cells use energy and nutrients in hormone-receptor positive, HER2-negative tumors during planned surgery. It may help researchers understand the cancer better by comparing tumor tissue with nearby normal tissue.
New Brunswick, New JerseyAges 18 years+ - NCT05683418RecruitingPhase 1
Study of a new drug for PIK3CA-mutated HR+ HER2- breast cancer
This early-stage study tests the safety and tolerability of TOS-358 in women with HR-positive, HER2-negative breast cancer that has a specific gene change (PIK3CA). It may help learn whether this targeted treatment is safe enough to move forward.
Chicago, IllinoisAges 18 years+ - NCT05704829RecruitingPhase 2
Trastuzumab-deruxtecan before surgery for HER2-positive early breast cancer
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT05677802Recruiting
Stress-reduction program for newly diagnosed triple-negative breast cancer
This study tests whether a structured stress-reduction program can help people with newly diagnosed triple-negative breast cancer (stages I–III). The goal is to see if the program is practical and beneficial for patients during treatment.
Cleveland, OhioAges 18 years+
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 + breast cancer?
- Yes. Clin2 currently lists 952 recruiting her2 + breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 + breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.